Enanta Pharmaceuticals, Inc. (ENTA) Coverage Initiated by Analysts at Royal Bank Of Canada

Equities researchers at Royal Bank Of Canada initiated coverage on shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.

ENTA has been the topic of several other research reports. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Robert W. Baird upped their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, August 8th. Finally, JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a report on Tuesday, July 11th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $36.00.

Enanta Pharmaceuticals (ENTA) opened at 44.92 on Thursday. The firm has a 50-day moving average price of $40.91 and a 200-day moving average price of $34.56. Enanta Pharmaceuticals has a one year low of $22.17 and a one year high of $45.74. The stock’s market cap is $857.52 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.05. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. Enanta Pharmaceuticals’s revenue was down 46.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.06) earnings per share. On average, equities analysts predict that Enanta Pharmaceuticals will post $1.14 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.truebluetribune.com/2017/09/17/enanta-pharmaceuticals-inc-enta-research-coverage-started-at-royal-bank-of-canada.html.

Several large investors have recently modified their holdings of the company. Texas Permanent School Fund lifted its position in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Texas Permanent School Fund now owns 10,146 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 85 shares in the last quarter. ClariVest Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 0.8% in the first quarter. ClariVest Asset Management LLC now owns 13,400 shares of the biotechnology company’s stock valued at $413,000 after acquiring an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its position in shares of Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 110 shares in the last quarter. Eqis Capital Management Inc. lifted its position in shares of Enanta Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 31,565 shares of the biotechnology company’s stock valued at $1,136,000 after acquiring an additional 173 shares in the last quarter. Finally, Mason Street Advisors LLC lifted its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 212 shares in the last quarter. Institutional investors and hedge funds own 66.07% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply